| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. (Chemical Entities of Biological Interest Ontology, CHEBI_70752) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=DABIGATRAN |
| Similar Terms | |
| Downloads & Tools |
9 interacting proteins for the DABIGATRAN drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) | 11.7627 |
| HYOU1 | hypoxia up-regulated 1 | 11.7627 |
| HNMT | histamine N-methyltransferase | 2.35253 |
| ADK | adenosine kinase | 1.06933 |
| NQO2 | NAD(P)H dehydrogenase, quinone 2 | 0.691921 |
| F2 | coagulation factor II (thrombin) | 0.625674 |
| APOB | apolipoprotein B | 0.490111 |
| CYP3A5 | cytochrome P450, family 3, subfamily A, polypeptide 5 | 0.289246 |
| CYP2D6 | cytochrome P450, family 2, subfamily D, polypeptide 6 | 0.0192515 |